Blood group as a prognostic indicator in breast cancer

P J HOLDSWORTH, J THOROGOOD, E A BENSON, A D CLAYDEN

Abstract

A retrospective analysis of 1001 patients with invasive breast cancer showed a difference in survival between patients with different blood groups. Analysis of time from operation to local recurrence and to general recurrence reinforced this finding. The difference between blood groups became increasingly significant after accepted prognostic factors were allowed for. Patients at particularly high risk of early death or general recurrence were those with blood groups B and AB, those with group AB having a greater relative local recurrence rate.

Introduction

Several factors are known to influence survival of women with breast cancer,¹ but little is known of the prognostic influence of different blood groups. In a series of 1323 radical mastectomies for cancer carried out from 1940 to 1965 Donegan associated 10 year survival with various constitutional, clinical, and pathological factors, and analysis of the blood groups of 986 patients showed that a good survival was associated with blood group AB (10 year relative survival 66.2%) and a poor survival with blood group B (10 year relative survival 27%).² We present a similar sized series and compare the results.

Patients and methods

Between 1976 and 1981 in a study of prognostic factors in breast cancer the Yorkshire Breast Cancer Group collected 1186 cases of operable, invasive breast cancer (T_0 - T_3 , N_0 - N_{1B} , M_0); information about blood groups was available for 1001 of these. The remaining

FIG 1—Survival of patients with breast cancer according to blood group.

TABLE 1—Distribution of blood groups

	Blood group				Total
	O	A	B	AB	
Women with operable breast cancer (%)	485 (48.4)	403 (40.3)	82 (8.2)	31 (3.1)	1001
Women in Yorkshire Region* (%)	462.82 (46.2)	419.73 (41.9)	85.65 (8.6)	32.80 (3.3)	1001

*Figures from Blood Transfusion Service (n = 30 473) scaled down to proportions out of 1001.

TABLE 2—Log rank survival analysis of patients with breast cancer

Blood group	No of patients	No of deaths observed	No of deaths expected	Relative death rate	Relative general recurrence rate	Relative local recurrence rate
O	485	120	130.69	0.92	0.93	0.87
A	403	106	107.29	0.99	0.98	1.05
B	82	27	19.97	1.35	1.27	1.14
AB	31	12	7.05	1.70	1.80	2.10
Total	1001	265				
p				0.077	0.077	0.038

General Infirmary at Leeds, Leeds LS1 3EX

P J HOLDSWORTH, FRCSed, surgical registrar, department of urology
E A BENSON, MA, FRCS, consultant surgeon

Yorkshire Regional Cancer Organisation, Cookridge Hospital, Leeds LS16 6QB

J THOROGOOD, BSc, data processor

Department of Community Medicine, University of Leeds, Leeds LS2 9JT

A D CLAYDEN, PHD, senior lecturer in medical statistics

Correspondence to: Mr P J Holdsworth.

185 cases were not included because certain data were missing. The numbers of patients available for analysis at the time of operation and one, two, and five years later were 1001, 966, 883, and 259, respectively. These were not survival figures but reflect the fact that only a proportion of the patients had undergone the follow up at five years. The standard treatment used was simple mastectomy and usually radiotherapy if axillary nodes were affected.

Results

The distribution of particular blood groups in the population of women presenting with operable breast cancer was not significantly different from that of women in the areas of Yorkshire covered by the contributing surgeons ($\chi^2 = 1.98$; $p = 0.57$) (table 1).³

Log rank analysis⁴ showed a difference in survival between patients with different blood groups. Patients with blood groups B and AB had higher relative rates of death and general recurrence than those with groups O and A when analysed as four separate groups (table II, figs 1 and 2), but the differences just failed to reach significance ($p = 0.077$). A significant result was, however, observed when the time to local recurrence was analysed ($p = 0.038$) (fig 3), and in this case patients with group AB alone had a high relative local recurrence rate. When the high risk groups, B and AB, were combined and compared with the combined low risk groups, O and A, a significant difference in survival ($p = 0.015$) and general recurrence ($p = 0.023$) was seen (figs 4 and 5). This combination of groups increased the

FIG 2—Rate of general recurrence of breast cancer according to blood group.

FIG 3—Survival without local recurrence in patients with breast cancer according to blood group.

FIG 4—Survival of patients with breast cancer with high risk and low risk blood groups.

p value for the analysis of time to local recurrence to 0.063 (fig 6). Thus the type of blood group may have a different effect in an analysis of time to local recurrence (in which patients with group AB were at particularly high risk) than in an analysis of time to general recurrence or death (in which those with groups B and AB had high relative rates of death and general recurrence). To see whether established prognostic factors¹ accounted for the difference in survival we analysed the results allowing for individual factors such as TNM stage, clinical stage, etc (table III). Rhesus factor was also included because of its relation to blood groups. By taking these factors into account we ensured that the overall difference between blood groups was not biased by the presence of a particular factor. All results

remained significant, and most increased in significance, when these prognostic factors were allowed for individually. The relative risk⁵ of patients having B or AB blood group in all cases lay between 1.5:1 and 1.8:1.

To examine the influence of more than two prognostic factors simultaneously we used Cox's regression model³ on the established key prognostic factors, T stage, M stage, clinical stage, pathological grade, and pathological nodal invasion. This tested whether blood group could make any useful contribution to a model of survival, and a stepwise analysis was used to identify a set of independent variables that were significantly related to survival. T stage, N stage, and blood group were found to enter the model, and the contribution of blood group was significant ($p=0.013$) with a relative risk of 1.57 (95% confidence interval 1.12-2.21). The pathological factors grade and nodal invasion, together with blood group, all entered the model, and blood group again made a significant contribution ($p=0.025$).

FIG 5—Survival without general recurrence in patients with breast cancer with high risk and low risk blood groups.

FIG 6—Survival without local recurrence in patients with breast cancer with high risk and low risk blood groups.

TABLE III—Results of analysis controlling for effect of blood group and other prognostic factors on relative risk of death of patients with breast cancer

Factor allowed for	Relative risk (95% confidence limits)	p Value
Blood group	1.52 (1.08-2.14)	0.015
Blood group and:		
Palpable axillary nodes	1.51 (1.08-2.12)	0.016
Cancerous axillary nodes	1.60 (1.13-2.28)	0.008
T stage	1.64 (1.17-2.31)	0.004
N stage	1.51 (1.08-2.12)	0.017
Clinical stage	1.63 (1.16-2.30)	0.004
Pathological size of lump	1.62 (1.14-2.31)	0.007
First grade	1.51 (1.06-2.15)	0.022
Grade assessed at one centre	1.64 (1.16-2.33)	0.005
Tubules	1.67 (1.13-2.46)	0.010
Pleomorphism	1.79 (1.21-2.65)	0.003
Mitotic activity	1.72 (1.16-2.55)	0.006
Nodes invaded	1.47 (1.02-2.10)	0.036
T stage and M stage	1.57 (1.12-2.21)	0.013
Grade and nodes invaded	1.56 (1.08-2.27)	0.025
Clinical stage and grade and nodes invaded	1.69 (1.17-2.46)	0.009
Rhesus factor	1.51 (1.08-2.12)	0.017

with a relative risk of 1.56 (95% confidence interval 1.08-2.27). Finally, the effect of the four variables clinical stage, pathological grade, nodal invasion, and blood group together was examined. Blood group again made a significant contribution ($p=0.009$) with a relative risk of 1.69 (95% confidence interval 1.17-2.46).

Discussion

If blood group is associated with survival from other diseases⁶ there would be some bias in the population towards older women. At the time of analysis, however, the only suitable information available on blood groups in the population was that from the Blood Transfusion Service, and a non-significant result was obtained when distributions were compared. In addition, the analysis was concerned with prognosis, not the risk of development of breast cancer.

In contrast with the results obtained in this series Donegan found a "good" relative survival in patients with blood group AB, although figures for other blood groups were comparable.² The exact reason for this difference is not clear as he did not discuss his findings in detail. We can only postulate possible causes such as differences in the distribution of blood groups in the population studied or different methods of selecting cases for the study.

By applying the log rank method and Cox's model we found that the type of blood group retained its significance and could

be regarded as an independent factor of prognostic value, not explained by the presence of known clinical or pathological risk factors. We therefore believe that blood group should be considered in addition to these risk factors when a patient's prognosis is assessed.

We thank the following members of the Yorkshire Breast Cancer Group who participated in the study: Mr W G Harris, Mr E A Benson, Mr D S Hopton, Mr R Hall, Mr T S Matheson, Mr F G Smiddy, Mr W A F McAdam, Mr V S D Logan, Mr V K Modgill, Mr K Wilson, Mr G Wilson, Mr M Whittaker, Mr J J Price, Mr M Edwards, Professor C A Joslin, Dr D Ash, Dr S C Cartwright, Dr H G Frank, Dr R Cartwright, Dr A D Clayden, Dr P Cowen, Dr J Dossett, and Dr D Mackinnon.

References

- 1 Haybittle JL, Blamey RW, Elston CW, *et al.* A prognostic index in primary breast cancer. *Br J Cancer* 1982;45:361-6.
- 2 Donegan WL. Mastectomy in the primary management of invasive mammary carcinoma. *Adv Surg* 1972;6:1-102.
- 3 Kopec AC. *The distribution of blood groups in the United Kingdom*. London: Oxford University Press, 1979.
- 4 Peto R, Pike MC, Armitage P, *et al.* Design and analysis of randomised clinical trials requiring prolonged observation of each patient. *Br J Cancer* 1977;35:1-39.
- 5 Cox DR. Regression models and life-tables. *Journal of the Royal Statistical Society, Series B* 1972;34:187-220.
- 6 Hall R, Bunch GA, Humphrey CS. Arteriosclerosis, duodenal ulcer, blood group, and secretor status. *Br Med J* 1971;iii:767.

(Accepted 20 December 1984)

SHORT REPORTS

Unithiol in Wilson's disease

Patients with Wilson's disease, after initial "decuppering" with penicillamine or trientine dihydrochloride, require lifelong treatment, albeit at a reduced dose, to maintain their copper balance. Unfortunately, 5-10% of patients develop intolerance to penicillamine,¹ some of whom also develop intolerance to trientine dihydrochloride. I describe one such patient who was subsequently managed with unithiol (Dimaval; (2,3)-dimercaptopropane-(1)-sulphonate sodium salt). Other possible drugs are zinc salts (sulphate or acetate)² and tetrathiomolybdate.³

Case report

A 13 year old boy presented with fluid retention. Biopsy showed cirrhosis of the liver. He was treated symptomatically. Three years later his younger sister died suddenly of liver failure; a genetic illness was suspected. A year later he developed dysarthria, and examination showed hepatosplenomegaly, gynaecomastia, and Kayser-Fleischer rings. His serum copper concentration was 4.1 $\mu\text{mol/l}$ (26 $\mu\text{g}/100\text{ ml}$) and urine copper excretion over 3.1 $\mu\text{mol}/24\text{ h}$ (200 $\mu\text{g}/24\text{ h}$). Penicillamine was started, and symptoms of the hepatic and the neurological disease rapidly cleared; after two years, however, he developed severe systemic lupus and a nephrotic syndrome. Penicillamine was stopped and prednisolone 5 mg daily started.

The systemic lupus did not respond, and after two months he was referred

to this hospital for possible treatment with trientine dihydrochloride. The prednisolone was increased to 60 mg daily, which rapidly controlled the arthropathy and serositis but not the proteinuria. Trientine dihydrochloride was started, and he was discharged with instructions to reduce the dose of prednisolone slowly under local medical supervision. After two months, when he was taking prednisolone 5 mg daily, the systemic lupus recurred. Trientine dihydrochloride was stopped and prednisolone increased to 10 mg daily. For 15 months he remained well apart from heavy proteinuria. His serum copper concentration showed that his body stores of the metal were reaccumulating. Blood and urine copper concentrations had risen, and studies with radioactive copper showed that the liver was less efficient at sequestering copper and clearing the plasma of the radioisotope (table).⁴ He was therefore given a test dose of unithiol, an alternative chelating agent, which induced good cupruresis. A maintenance dose of 200 mg twice daily was started. Copper excretion rose to 31.5-47.2 μmol (2000-3000 μg) daily.

This treatment was continued, plus prednisolone 10 mg daily, from February 1982, and, apart from heavy proteinuria, his health remained good. His blood and urine copper concentrations fell, though basal urine copper excretion was still higher than when penicillamine was stopped.

Comment

Although this particular water soluble analogue of dimercaprol has been used in Eastern Bloc countries for some time, it has not been available in western Europe, so little is known of its toxicity. One problem with the parent compound, dimercaprol, was the

Results of copper studies during treatment for Wilson's disease

Date	Treatment and its duration	Plasma copper ($\mu\text{mol/l}$)	Basal urine copper ($\mu\text{mol}/24\text{ h}$)	Urine copper after:			Radioactive copper (plasma 24 h:2 h ratio)
				Penicillamine ($\mu\text{mol}/24\text{ h}$)	Trientine dihydrochloride ($\mu\text{mol}/6\text{ h}$)	Unithiol ($\mu\text{mol}/6\text{ h}$)	
July 1977	Nil	4.1	3.1	21.9			
November 1979	Penicillamine, 2 years	0.9	0.6		2.1		
November 1980	Trientine dihydrochloride, 1 year	0.8	0.6		1.5		0.15
March 1982	Nil, 15 months	6.8	12.1		40.7	20.7	0.29
February 1983	Unithiol, 1 year	1.9	2.5		2.9	3.1	
March 1984	Unithiol, 2 years	1.7	1.7			2.4	

Conversion: SI to traditional units—Plasma copper: 1 $\mu\text{mol/l} \approx 6.4\text{ }\mu\text{g}/100\text{ ml}$. Urine copper: 1 $\mu\text{mol}/24\text{ h} \approx 63.6\text{ }\mu\text{g}/24\text{ h}$.